Real-time enrollment status for this treatment-resistant schizophrenia clinical trial
Current Status
Recruiting
Checked: August 29, 2026 at 4:01 PM UTC
| NCT Number | NCT07184619 |
| Recruiting Status | Recruiting |
| Condition | Treatment-resistant Schizophrenia |
| Phase | PHASE3 |
| Target Enrollment | 400 participants |
| Active Locations | 5 sites in the US |
| Sponsor | Newron Pharmaceuticals SPA |
| Last Updated on CT.gov | July 30, 2026 (Jul 30, 2026) |
As of August 29, 2026: Clinical trial NCT07184619 is currently recruiting participants. This phase3 study for treatment-resistant schizophrenia is actively seeking new participants at 5 locations across the United States. The study is sponsored by Newron Pharmaceuticals SPA. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07184619 is actively recruiting participants as of August 29, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 5 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07184619 was last updated Jul 30, 2026 (July 30, 2026). HelloStudys verifies this status automatically.